Literature DB >> 35254577

Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.

Pedro Antonio Cascales Campos1, Alida González Gil2.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35254577     DOI： 10.1245/s10434-022-11501-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  7 in total

1.  Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.

Authors:  Simone N Koole; Christiaan van Lieshout; Willemien J van Driel; Evi van Schagen; Karolina Sikorska; Jacobien M Kieffer; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H Hermans; Ignace H de Hingh; Jacobus van der Velden; Henriette J Arts; Leon F A G Massuger; Arend G Aalbers; Victor J Verwaal; Koen K Van de Vijver; Neil K Aaronson; Harm van Tinteren; Gabe S Sonke; Wim H van Harten; Valesca P Retèl
Journal:  J Clin Oncol       Date:  2019-06-28       Impact factor: 44.544

2.  A Comment on a Recent Failed HIPEC Trial.

Authors:  Luis Chiva; Philip Harter; Felix Boria; Pedro Ramirez
Journal:  Ann Surg Oncol       Date:  2022-02-15       Impact factor: 5.344

3.  Letter to the Editor: Comment on ''Cytoreductive Surgery with or without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial''.

Authors:  Vandré Cabral Gomes Carneiro; Nathalia Moreira Ramalho
Journal:  Ann Surg Oncol       Date:  2022-02-15       Impact factor: 5.344

4.  Enigma of Hyperthermic Intraperitoneal Chemotherapy with Interval Cytoreduction Surgery: Need to Push More Boundaries!

Authors:  Sriniket Raghavan; Swapnil Patel; Amar Prem; Durgatosh Pandey
Journal:  Ann Surg Oncol       Date:  2022-02-20       Impact factor: 5.344

5.  Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".

Authors:  B Noiret; N Bakrin; C Eveno
Journal:  Ann Surg Oncol       Date:  2022-02-22       Impact factor: 5.344

6.  The Debatable Role of HIPEC in Ovarian Cancer.

Authors:  Eduardo Paulino; Andreia Cristina Melo
Journal:  Ann Surg Oncol       Date:  2022-03-07       Impact factor: 5.344

7.  Cytoreductive Surgery With or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial.

Authors:  Cascales Campos Pedro Antonio; González Gil Alida; Gil Gómez Elena; González Sánchez Rocío; Martínez García Jerónimo; Alonso Romero José Luis; Nieto Díaz Aníbal; Barceló Valcárcel Francisco; Gómez Ruiz Álvaro Jesús; Ramírez Romero Pablo; Gil Martínez José
Journal:  Ann Surg Oncol       Date:  2021-11-23       Impact factor: 5.344
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.